Detecting bacterial endotoxins in a pharmaceutical product or a medical device is not an easy task. That’s why it’s important to find the solution that best fits your organization and your products.
The first step, before even looking for a supplier, is to define clear specifications. It may feel like a waste of time, but trust us, it will save you a lot later! To help you, we wrote an article listing 8 key criteria to include in your specifications.
Now, you’re ready to reach out to BET (Bacterial Endotoxin Test) suppliers. To guide your search, we ran a large survey in the SuperMicrobiologists community to find out which BET supplier they prefer.
Here are the results:
- Associates of Cape Cod
- Charles River
- Challengers:
Important information : The results of this survey combine both traditional LAL-based and recombinant methods.
While recombinant solutions clearly represent the future of BET, most of the responses we received still concern LAL-based solutions.
To provide a representative overview of the current market, we asked each supplier to emphasize the solution they are currently promoting most actively, whether LAL or recombinant.
Associates of Cape Cod, Inc.

Associates of Cape Cod, Inc. (ACC), a global leader in bacterial endotoxin testing (BET) solutions, transformed BET in 1974 with the introduction of its gel-clot test reagent and then again with its chromogenic and turbidimetric tests. They’ve transformed the industry again with PyroSmart NextGen®, a groundbreaking recombinant BET solution.
Technology description
PyroSmart NextGen® (rCR) is a sustainable recombinant LAL reagent technology for bacterial endotoxin testing (BET). Utilizing the same LAL cascade as traditional LAL reagents while eliminating the potential for (1→3)-β-D-glucan cross-reactivity.
Whether you’re testing standard water samples or high-sensitivity products, PyroSmart NextGen® delivers consistent results with sensitivity down to 0.005 EU/mL with a microplate reader.
With the US Pharmacopeia’s approval of Chapter <86>, biopharmaceutical manufacturers can more easily incorporate (rCR) testing methods into their quality testing. Plus, PyroSmart NextGen® enhances the sustainability profile by providing a sustainable, animal-free alternative to traditional LAL. This synthetic alternative reagent reduces supply chain challenges while supporting ESG goals.
Key strengths:
- No Animal Content: Horseshoe Crab Blood Free
- Mimics the traditional LAL Cascade: Allows for same preparation steps, instrumentation and setup
- Sustainable Technology: Helps support your corporate sustainability goals
Automation available
PyroSmart NextGen® is engineered for seamless integration into automated, high-throughput workflows. Its compatibility with microplate reader platforms, including the BioTek Epoch 2 and ACC’s Pyros® eXpress software enables labs to streamline bacterial endotoxin testing with minimal disruption. It’s also fully compatible with the Andrew+ pipetting robot, a flexible, benchtop liquid handling system that automates sample preparation.
This flexible, automation-ready format helps reduce manual handling, improve data integrity, and accelerate QC timelines, all while supporting your sustainability and regulatory goals.
Charles River

Endosafe® LAL Cartridges are FDA-licensed, pharmacopeia-aligned, and deliver quantitative results in ~15 minutes. They eliminate manual standard preparation, simplify training, and reduce error, lowering the risk of invalid results that trigger costly investigations, retests, and delays in batch release.
Technology description
Endosafe® Cartridge Technology uses a kinetic chromogenic method for precise endotoxin quantitation without user-prepared curves. The system compares reaction times against a validated, archived standard curve. Each lot undergoes performance testing and ships with a calibration code and Certificate of Analysis.
This streamlined approach—used in both LAL and recombinant cartridges—eliminates curve prep, reduces analyst variability, and minimizes uncertainty.
The result: rapid, reproducible testing with fewer manual steps and greater consistency across lots, sites, and users.
Key strengths :
- Efficiency at scale – Results in ~15 minutes with minimal prep or training. Cartridges remove manual curve setup, reduce invalids, and keep your lab moving—whether you’re releasing a lot or troubleshooting a spike.
- Standardized, future-ready platform – A single method, compatible with both traditional LAL and animal-free rCR, across three instruments—from benchtop to automated. Seamless switching simplifies qualification, SOPs, and regulatory alignment globally.
- Trusted and sustainable: Built on the kinetic chromogenic method adopted worldwide as a reliable standard. With 95% less crab material—and a 100% animal-free option—Endosafe helps meet sustainability and 3Rs goals without changing systems.
Automation available
Automation begins with every cartridge assay with the Archived Standard Curve (ASC), prepared under stricter criteria than pharmacopeias to remove manual curve preparation, reduce variability, and cut human input.
Endosafe® cartridges then scale across three platforms:
- nexgen-PTS™ for point-of-use testing
- nexgen-MCS™ for higher throughput
- Nexus 200™ for fully automated runs with barcoding and audit trails.
Recombinant Solution available
Endosafe® Trillium™ cartridges and reagents replicate the natural LAL reaction using a full three-factor enzymatic cascade. Fully compatible with Endosafe instruments and software, Trillium delivers the same performance as LAL cartridges while advancing sustainability goals and the 3Rs: Replace, Reduce, and Refine.
Number of sites equipped in the world
Since its introduction, more than 20 million cartridges have been produced, and over 20,000 cartridge testing systems have been deployed worldwide, supporting labs from early development to global commercial release.
The other BET supplier mentioned by the SuperMicrobiologists is Lonza.
Challengers 100% recombinant solution : bioMérieux (rFC)

ENDONEXT™, a bioMérieux Pharma QC solution, pioneered rFC-based endotoxin testing 15 years ago, offering an ethical, innovative alternative to animal-derived methods. Manufactured in Bernried (Germany), ENDONEXT™ helps ensure reliable endotoxin control in pharmaceutical products, supporting patient safety and regulatory compliance, as described in a comprehensive FDA Master file.
Principle of the test
Recombinant Factor C (rFC) testing uses a synthetic version of the endotoxin-sensitive protein from horseshoe crab blood, produced in vitro to avoid animal use.
Upon binding to bacterial endotoxins (LPS), Factor C activates and cleaves a fluorogenic substrate, generating a measurable signal.
Unlike LAL, rFC is specific to endotoxins, eliminating β-glucan interference and false positives. This ethical, consistent method supports robust endotoxin testing in pharma and medical device applications.
Key strengths
- Ethical: No use of horseshoe crab blood – rFC is recombinantly produced, preserving marine biodiversity.
- Specific: 100% endotoxin specificity – rFC targets only Factor C, avoiding interference from β-glucans and reducing false positives compared to LAL.
- Reliable: Recombinant production ensures consistent performance across batches and a secure global supply, independent of crab populations, supporting reproducibility and lab efficiency.
Automation available
ENDONEXT™ solution simplifies automation adoption thanks to ENDOZYME® II GO Plates.
The most challenging part of adopting automation in BET with microplate kits is building the CSE curve and preparing PPCs, since the CSE must be reconstituted in advance by long vortexing. With ENDOZYME® II GO PLATES, the plates are pre-filled with both the curve and PPCs. This step, performed by the supplier, not only ensures accurate CSE concentrations but also makes it possible for simple pipetting systems (such as Integra Assist Plus or Andrew+) or full automation platforms (such as Tecan Fluent) to streamline the process.
For example, due to endpoint reading link to rFC technology, with the Tecan Fluent system it is possible to run 120 samples in 45 minutes with a sensitivity of 0.05 EU/ml, which is ideal for water testing or in 75 minutes with a sensitivity of 0.005 EU/ml. This “second level” of automation improves operational efficiency, reduces human error, and strengthens data integrity.
Recombinant Solution available
ENDONEXT™ is an exclusively ethical solution for endotoxin detection, based on recombinant Factor C (rFC) technology. The portfolio offers flexibility to meet diverse laboratory needs, including ENDOZYME® II, ENDOZYME® II GO Plates, and GO STRIPS for both high and low throughput.
For complex sample matrices, the patented ENDOLISA® kit provides robust rFC-based detection, ensuring reliable and horseshoe crab-free testing.
Number of sites equipped in the world
Around 500 worldwide users site of recombinant rFC bioMerieux solution
Challenger automation : Sievers Veolia

Sievers Instruments (Veolia Group), is a provider for analytical instrumentation for TOC & Conductivity measurements, Bacterial Endotoxins Testing (BET), and rapid bioburden monitoring.
Designed to make complex measurements simple, the Sievers line includes microfluidic-based technology that streamlines endotoxin testing methods and represents a sustainable, compliant, and genuinely modern approach.
Principle of the test
The Sievers Eclipse Platform consists of three components – an analyzer, microplate, and software – and is designed for quality control testing of water and drug products within pharmaceutical and medical device markets.
The Eclipse uses commercially available LAL and Recombinant Cascade Reagents (rCR), using 90% less reagents compared to traditional methods.
Each microplate features a pre-deposited 5-point standard curve, eliminating the need to prepare your own standard curve. Up to 21 samples can be run simultaneously alongside Positive Product Controls, also pre-dried on the microplate. The platform automatically delivers reagent to samples in a 1:1 ratio using centripetal force.
Key strengths
- Flexibility in reagent choice: Use an LAL Manufacturer’s chromogenic reagent or rCR, and compatible with Wako’s turbidimetric reagent.
- Ergonomics: Reduced pipetting steps minimize ergonomic stress on the analyst.
- Accuracy: Pre-deposited standard curve and PPCs minimize human error.
Automation available
Significant efficiency gains without robotics.
Today’s endotoxin testing is not limited to choosing between manual processes or robotic systems. The Sievers Eclipse from Veolia delivers the efficiency gains of automation – streamlined setup, reduced human error, and consistent results – through a modern benchtop platform that requires no robotic infrastructure. You get automated precision without the cost of traditional robotic systems.
Recombinant Solution available
The Sievers Eclipse is compatible with all commercially available recombinant Cascade Reagents (rCR).
For enhanced sustainability, the Eclipse uses 90% less reagent, allowing a single vial to support 2-3 assays instead of just one.